Effectiveness of the Fascial Distortion Model in Temporomandibular Disorders: A Randomized Sham-controlled Trial

August 3, 2026 updated by: Harun Gençosmanoğlu, Karabuk University

Investigation of the Effectiveness of Manual Therapy Based on Fascial Distortion Model in Individuals With Temporomandibular Disorder: A Randomized Sham-controlled Trial

The aim of the study was to investigate the effectiveness of Manual Therapy Based on the Fascial Distortion Model in individuals with temporomandibular disorders compared to sham control. Individuals diagnosed with temporomandibular disorder will be randomly assigned to groups as Group 1 (Manual Therapy Based on Fascial Distortion Model) and Group 2 (Sham Control). Head posture, cervical and temporomandibular joint range of motion, cervical muscle performance, pain intensity, pressure pain thresholds, temporomandibular disorder severity, disability, dysfunction, health-related quality of life, kinesiophobia, and central sensitization will be assessed.

Study Overview

Detailed Description

Interventions are needed to address head posture, cervical and temporomandibular joint range of motion, cervical muscle performance, pain intensity, pressure pain thresholds, temporomandibular disorder severity, disability, dysfunction, health-related quality of life, kinesiophobia, and central sensitization in individuals with temporomandibular disorder (TMD). This study aims to examine the effectiveness of Manual Therapy Based on the Fascial Distortion Model in individuals with TMDs compared to sham control over a 4-week period. Individuals with TMD will be randomized into Group 1 (Fascial Distortion Model-based Manual Therapy) or Group 2 (Sham Control). Interventions will be conducted once a week in a clinical setting. Head posture will be measured by lateral photogrammetry, cervical range of motion will be measured by an inclinometer, temporomandibular range of motion will be measured by a vernier caliper, cervical muscle performance will be measured by Cervical Spine Functional Strength Test, and pressure pain threshold will be measured by an algometer. Pain intensity will be assessed using the Graded Chronic Pain Scale (Revised) and the Short-Form McGill Pain Questionnaire. TMD severity will be assessed using the Fonseca Anamnestic Index. Mandibular Function Impairment Questionnaire will be used to assess dysfunction. Disability will be evaluated using the Craniofacial Pain and Disability Inventory. Health-related quality of life will be assessed using Short Form-36. Kinesiophobia will be assessed with the Tampa Kinesiophobia Scale; central sensitization will be assessed with the Central Sensitisation Inventory.

All outcomes will be measured at baseline and end of the study, while pain intensity and pressure pain thresholds will also undergo intermediate assessments (2nd and 3rd week).

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Karabük Province
      • Merkez, Karabük Province, Turkey (Türkiye), 78050
        • Recruiting
        • Karabuk University
        • Contact:
        • Principal Investigator:
          • Harun Gençosmanoğlu, PT, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Having temporomandibular joint complaints and being diagnosed with temporomandibular disorder according to the Diagnostic Criteria for Temporomandibular Disorders Axis I
  • Understand and be willing to answer assessment questions
  • A temporomandibular joint complaint for the last three months
  • Pain in the jaw, face or neck

Exclusion Criteria:

  • Has a systemic disease (neurological, rheumatologic, oncologic, etc.) that may affect the temporomandibular joint, cervical spine and/or assessment
  • Any history of trauma that may have affected the cranio-cervico-facial region
  • Having undergone any surgical intervention in the cranio-cervico-facial region within the last six months
  • Receiving surgical treatment, medical treatment, splint therapy or physiotherapy for temporomandibular disorder in the last month
  • Radiotherapy in the head and neck region
  • Pregnancy or breastfeeding
  • Exercise therapy for craniocervical posture for the last month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Manual Therapy based Fascial Distortion Model
It will conducted for forty-five minutes once a week in a clinical setting for 4 weeks.
The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.
Other Names:
  • Typaldos Manual Therapy
Sham Comparator: Control
Sham application will conducted for forty-five minutes once a week in a clinical setting for 4 weeks.
The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Head posture
Time Frame: From enrollment to the end of treatment at 4th week
Lateral photogrammetry according to Eye-Tragus-Horizontal Angle, Pogonion-Tragus-C7 Angle, Tragus-C7-Horizontal Angle, Tragus-C7-Shoulder Angle, and Shoulder-C7-Horizontal Angle.
From enrollment to the end of treatment at 4th week
Cervical range of motions
Time Frame: From enrollment to the end of treatment at 4th week
Inclinometric measurements based on flexion, extension, lateral flexions, and rotations.
From enrollment to the end of treatment at 4th week
Temporomandibular range of motions
Time Frame: From enrollment to the end of treatment at 4th week
Digital vernier caliper measurements based on maximum pain-free mouth opening, maximum possible mouth opening, maximum possible assisted mouth opening, laterotrusions, and protrusion.
From enrollment to the end of treatment at 4th week
Cervical muscle performance
Time Frame: From enrollment to the end of treatment at 4th week
The Functional Strength Testing of the Cervical Spine was used to evaluate the cervical muscle performance. This is a test that functionally evaluates cervical muscle strength. Results of this test are assessed as functional, functionally fair, functionally poor, and nonfunctional. Six-to-eight repetitions for the flexion test and 20-25 s holding time for the other tests indicate that the test result is functional. Three-to-five repetitions for the flexion test and 10-19 s holding time for the other tests indicate that the test result is functionally fair. One-to-two repetitions for the flexion test and 1-9 s holding time for the other tests indicate that the test result is functionally poor. Zero repetition for the flexion test and 0 s holding time for the other tests indicate that the test result is nonfunctional. Each test was terminated at onset of pain, and the relevant value was recorded.
From enrollment to the end of treatment at 4th week
Pressure pain threshold
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Algometer. Tempormandibular joint, masseter, temporalis anterior, suboccipital muscle, trapezius, lateral epicondyle for both side.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Pain intensity in the last week
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Short-Form McGill Pain Questionnaire. Minimum and maximum values are 0 and 3 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Chronic pain intensity
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Graded Chronic Pain Scale (Revised). Scoring: Grade 1=mild, Grade 2=bothersome, Grade 3=high impact chronic pain. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Temporomandibular disorders severity
Time Frame: From enrollment to the end of treatment at 4th week
Fonseca Anamnestic Index. Minimum and maximum values are 0 and 10 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 4th week
Dysfunction
Time Frame: From enrollment to the end of treatment at 4th week
Mandibular Function Impairment Questionnaire. Minimum and maximum values are 0 and 4 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 4th week
Disability
Time Frame: From enrollment to the end of treatment at 4th week
Craniofacial Pain and Disability Inventory. Minimum and maximum values are 0 and 3 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 4th week
Health-related quality of life
Time Frame: From enrollment to the end of treatment at 4th week
Short Form-36. Its subdomains are physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
From enrollment to the end of treatment at 4th week
Kinesiophobia
Time Frame: From enrollment to the end of treatment at 4th week
Tampa Kinesiophobia Scale for Temporomandibular Disorders. Minimum and maximum values are 1 and 4 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 4th week
Central sensitization
Time Frame: From enrollment to the end of treatment at 4th week
Central Sensitisation Inventory. Minimum and maximum values are 0 and 4 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 4th week
Present pain intensity
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Visual Analog Scale. Minimum and maximum values are 0 and 10 cm, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Present pain intensity (ordinal)
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Present pain intensity scale of McGill Pain Questionnaire. Minimum and maximum values are 0 and 5 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Pain intensity in the last week (ordinal)
Time Frame: From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.
Numeric Pain Rating Scale. Minimum and maximum values are 0 and 10 points, respectively. Higher scores mean a worse outcome.
From enrollment to the end of treatment at 1st week, 2nd week, 3rd week, and 4th week.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Harun Gençosmanoğlu, PT, MSc, Karabuk University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 3, 2024

Primary Completion (Actual)

December 15, 2024

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

October 3, 2024

First Submitted That Met QC Criteria

October 3, 2024

First Posted (Actual)

October 4, 2024

Study Record Updates

Last Update Posted (Actual)

August 5, 2026

Last Update Submitted That Met QC Criteria

August 3, 2026

Last Verified

October 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe